Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randall W Alfano

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Bioconjugate Chemistry|September 30, 2009
Antibody internalization after cell surface antigen binding is critical for immunotoxin developmentShu-Ru Kuo, Randall W Alfano, Arthur E Frankel, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Journal of Crohn'S & Colitis|May 5, 2017
VEN-120, a Recombinant Human Lactoferrin, Promotes a Regulatory T Cell [Treg] Phenotype and Drives Resolution of Inflammation in Distinct Murine Models of Inflammatory Bowel DiseaseChristopher F MacManus, Colm B Collins, Tom T Nguyen, et al.
Molecular Cancer Therapeutics|May 17, 2008
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cellsRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Molecular Cancer Therapeutics|January 8, 2010
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinomaRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Molecular Cancer Research : MCR|April 18, 2009
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesisRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
The Journal of Biological Chemistry|November 3, 2007
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculatureShihui Liu, Hailun Wang, Brooke M Currie, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Bioconjugate Chemistry|September 30, 2009
Antibody internalization after cell surface antigen binding is critical for immunotoxin developmentShu-Ru Kuo, Randall W Alfano, Arthur E Frankel, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Journal of Crohn'S & Colitis|May 5, 2017
VEN-120, a Recombinant Human Lactoferrin, Promotes a Regulatory T Cell [Treg] Phenotype and Drives Resolution of Inflammation in Distinct Murine Models of Inflammatory Bowel DiseaseChristopher F MacManus, Colm B Collins, Tom T Nguyen, et al.
Molecular Cancer Therapeutics|May 17, 2008
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cellsRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Molecular Cancer Therapeutics|January 8, 2010
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinomaRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Molecular Cancer Research : MCR|April 18, 2009
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesisRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
The Journal of Biological Chemistry|November 3, 2007
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculatureShihui Liu, Hailun Wang, Brooke M Currie, et al.
Pageof 1